Following the start of patient inclusion in Europe, the first Asian center participating international study APPIRED lll has started patient recruitment.
Alloksys Life Sciences announced today that its international APPIRED lll clinical study has started with inclusion of the first patient in Eindhoven, the Netherlands.
Alloksys Life Sciences announced today that Kevin Driscoll has been appointed to its Supervisory Board.
Dr. Driscoll is a proven Healthcare executive with 30 years experience leading all aspects of innovation and R&D across the prescription drug, OTC drug, and food supplement businesses...
Alloksys Life Sciences BV, a biopharma SME based in The Netherlands, has been granted an Innovation Cedit (’Innovatiekrediet’) of 3.4 million EUR by the Netherlands Enterprise Agency for the execution of Phase 3 clinical trials leading to registration of RESCAP® (RESCuing Alkaline Phosphatase*) for the prevention and treatment of ischemic injury and inflammation mediated complications in cardiothoracic surgery (APPIRED III).
Dutch based Alloksys Life Sciences BV has signed and closed agreements with the fastest growing local pharmaceutical company in Singapore, ICM Pharma,Pte. Ltd. to invest €5.25 million (approximately S$8.1 million) for a minority stake in Alloksys and an exclusive license to market and produce RESCAP® (RESCuing Alkaline Phosphatase*) for prevention and treatment of ischemic injury and inflammation mediated complications in cardiothoracic surgery in Asia.
The Dutch based Alloksys Life Sciences BV and AMRIF BV have expanded their Management teams to gear up for stage 3 Clinical Trials